[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368963-105":59,"doc-detail-368963-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-ripk1-to-modulate-cell-death-and-tumour-microenvironment-in-cancer-therapy","Targeting RIPK1 to modulate cell death and tumour microenvironment in cancer therapy","","Receptor-interacting serine/threonine-protein kinase 1 (RiPK1) is crucial in regulating inflammation, apoptosis, and necroptosis. Accumulating evidence supports RiPK1 as a therapeutic target in cancer, where it suppresses immunogenic cell death and drives an immunosuppressive tumour microenvironment that promotes immune evasion, metastasis, and resistance. Targeting RiPK1 may overcome immune checkpoint blockade resistance and convert tumours into an immunologically hot phenotype. This review summarizes RiPK1 functions, roles in progression, and reported RiPK1-targeted inhibitors, highlighting remaining opportunities and challenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-ripk1-to-modulate-cell-death-and-tumour-microenvironment-in-cancer-therapy/368963/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-ripk1-to-modulate-cell-death-and-tumour-microenvironment-in-cancer-therapy/368963.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is RIPK1 considered important in cancer therapy?","Question",{"text":112,"@type":113},"RIPK1 regulates inflammation and multiple forms of programmed cell death, affecting immunogenicity and the tumour microenvironment. Evidence in the review links RIPK1 activity to immune evasion, metastasis, and therapeutic resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does targeting RIPK1 relate to immune checkpoint blockade resistance?",{"text":117,"@type":113},"The review states that targeting RIPK1 may overcome immune checkpoint blockade resistance. It may also convert tumours from immunologically cold to immunologically hot phenotypes.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review cover regarding RIPK1?",{"text":121,"@type":113},"The review summarizes RIPK1 biological functions and its roles in cancer progression via tumour immune microenvironment, metastasis, and chemoresistance. It also lists identified RIPK1-targeted inhibitors and notes remaining opportunities and challenges for further investigation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368963,1790230281,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of EnzymE InhIbItIon and mEdIcInal chEmIstry 2025, Vol. 40, no. 1, 2593800  \n[https://doi.org/10.1080/14756366.2025.2593800](https://doi.org/10.1080/14756366.2025.2593800)  \nReview ARticle    \nTargeting RIPK1 to modulate cell death and tumour microenvironment in cancer therapy  \nJing chena,b\\#, Shijie Maoc\\#, lingling Huangd, tao Zhud and Yun Beia,b  \nadepartment of Pharmacy, huzhou central hospital, fifth school of clinical medicine of zhejiang chinese medical university, huzhou, zhejiang, china; bdepartment of Pharmacy, affiliated huzhou hospital, zhejiang university school of medicine, huzhou, zhejiang, china; cdepartment of Pharmacy, huzhou third municipal hospital affiliated to huzhou university, huzhou, zhejiang, china; ddepartment of Pharmacy, the second affiliated hospital, zhejiang university school of medicine, hangzhou, china  \nABSTRACT  \nReceptor-interacting serine/threonine-protein kinase 1 (RiPK1) is crucial in regulating inflammation, apoptosis, and necroptosis. Accumulating evidence highlights RiPK1 as a promising therapeutic target for various human diseases, including neurodegenerative disorders, autoimmune diseases, and [cancer. in](cancer. in) tumour cells, RiPK1 suppresses immunogenic cell death, promotes an immunosuppressive tumour microenvironment, which facilitates immune evasion, metastatic progression, and therapeutic resistance, contributing to an immunologically cold tumour phenotype. therefore, targeting RiPK1 represents a promising therapeutic approach to overcome immune checkpoint blockade resistance and convert tumours into an immunologically hot phenotype. in this review, we summarise the biological functions of RiPK1 and elaborate on its roles in cancer progression in terms of the tumour immune microenvironment, tumour metastasis, and chemoresistance. Furthermore, we enumerate several identified RiPK1-targeted inhibitors with potential for cancer therapy. Although RiPK1 has been proposed as a potential anticancer target, there are still great opportunities and challenges that require further investigation.  \nGRAPHICAL ABSTRACT  \nAbbreviations: RiPK1: Receptor-interacting serine/threonine-protein kinase 1; tMe: tumour microenvironment; PcD: programmed cell death; eR: endoplasmic reticulum; MOMP: mitochondrial outer membrane permeability; icD: immunogenic cell death;  \nDAMPs: damage-associated molecular patterns; icB: immune checkpoint blockade; RiP: Receptor-interacting protein; KD: kinase domain; iD: intermediate domain; RHiM: RiP homotypic interaction motif; DD: death domain; PtMs: post-translational modifications; iKK: iκB kinase; RDA: RiPK1-mediated apoptosis; MlKl: mixed lineage kinase domain-like  \nprotein; PiP: phosphatidylinositol phosphate; tNBc: triple-negative breast cancer; Dcs:  \nARTICLE HISTORY  \nReceived 23 August 2025 Revised 11 October 2025 Accepted 16 November 2025  \nKEYWORDS  \ncancer; necroptosis; RiPK1; tumour metastasis; tumour microenvironment  \nCONTACT tao zhu  [euzhutao@zju.edu.cn](euzhutao@zju.edu.cn)  department of Pharmacy, the second affiliated hospital, zhejiang university school of medicine, hangzhou, china; yun bei  [11918128@zju.edu.cn](11918128@zju.edu.cn)  department of Pharmacy, huzhou central hospital, fifth school of clinical medicine of zhejiang chinese medical university, huzhou, zhejiang, china.  \n\\#these authors contributed equally to this work.  \n© 2025 the author(s) . Published by Informa uK limited, trading as taylor & francis Group.  \nthis is an open access article distributed under the terms of the creative commons attribution license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. the terms on which this article has been published allow the posting of the accepted manuscript in a repository by the author(s) or with their consent.  \n2  J. cHeN et Al.  \ndendritic cells; Rcc: ","cbCaicq3Pet92Mhl","https://ap.wps.com/l/cbCaicq3Pet92Mhl","pdf",1646693,"English","# Introduction\n## Cell death types and relevance to disease\n## Apoptosis pathways\n# Targeting RIPK1 in cancer therapy\n## RiPK1 functions in tumour immune microenvironment\n## RiPK1-mediated metastasis and chemoresistance\n## RiPK1-targeted inhibitors and therapeutic prospects","[{\"question\":\"Why is RIPK1 considered important in cancer therapy?\",\"answer\":\"RIPK1 regulates inflammation and multiple forms of programmed cell death, affecting immunogenicity and the tumour microenvironment. Evidence in the review links RIPK1 activity to immune evasion, metastasis, and therapeutic resistance.\"},{\"question\":\"How does targeting RIPK1 relate to immune checkpoint blockade resistance?\",\"answer\":\"The review states that targeting RIPK1 may overcome immune checkpoint blockade resistance. It may also convert tumours from immunologically cold to immunologically hot phenotypes.\"},{\"question\":\"What does the review cover regarding RIPK1?\",\"answer\":\"The review summarizes RIPK1 biological functions and its roles in cancer progression via tumour immune microenvironment, metastasis, and chemoresistance. It also lists identified RIPK1-targeted inhibitors and notes remaining opportunities and challenges for further investigation.\"}]","Targeting RIPK1 to modulate cell death and tumour microenvironment in cancer therapy | PDF",1790179907,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2ae2641cd0dc58e2ae644c84134a153.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cfa0a82a01cb720f9a1dd9f93a93405.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/849fa88a6a55259ea8d9db0007d16f73.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd2243e90dc5efce428b74d76403d0cb.webp",980,1306]